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A B S T R A C T
The prevalence of the metabolic syndrome (MS) increases with advancing age. However, aging per se is
associatedwith increased prevalence of most of the abnormalities contributing to theMS.WhetherMS in
older people consistently identifies a true pathophysiological entity or a casual aggregation of aging-
associated metabolic abnormalities, remains to be fully elucidated. In the present study, we aimed to
evaluate whether in older subjects the aggregation of metabolic components of the MS, as defined by the
National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III), is consistent with a
single latent variable. Age, waist circumference, systolic and diastolic blood pressure, metabolic variables
were determined in 152 older (>70 years), non-diabetic, healthymen. Cronbach alphawas used to assess
the internal consistency of the components contributing to the MS. Structural equation modeling, using
the Normed Fit Index (NFI), the Root Mean Square Error of Approximation (RMSEA), the Comparative Fit
Index (CFI), and the Tucker-Lewis Index (TLI) was used to assess the fit to a model with a single latent
variable. The Cronbach alpha test showed low internal consistency among the metabolic variables
(a = 0.31). The calculated x2 values were 28.31 and 32.52 for model entering hypertension as
dichotomous variable and for model entering blood pressure values, respectively, both expressing low fit
to a model with a single latent variable. In both models, CFI (0.41 and 0.55), NFI (0.59 and 0.55), RMSEA
(0.25 and 0.22) and TLI (0.31 and 0.12) scores showed a low fit of the metabolic alterations to a single
latent variable. These findings suggest caution in making diagnosis of MS at older ages, since metabolic
and cardiovascular abnormalities being per se extremely common in elderly people, do not appear to
cluster together under a single common factor.
 2008 Published by Elsevier Ireland Ltd.
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The term MS denotes a condition recognized by the co-
occurrence of multiple metabolic abnormalities, including central
obesity, abnormal fasting glucose, dyslipidemia and hypertension
(Reaven, 1988; WHO, 1999). The MS has been associated with the
development of diabetes and increased risk of cardiovascular
morbidity and mortality, even in older subjects (Lempiainen et al.,
1999; Lakka et al., 2002;Wannamethee et al., 2005a;McNeill et al.,
2006), but several studies demonstrated that MS does not provide
incremental risk information above and beyond its individual
components (Yarnell et al., 1998; Lawlor et al., 2004a; Iribarren
et al., 2006; Sundstrom et al., 2006a). Moreover, there remains a
fundamental issue concerning the clinical nature of the syndrome,
that is, whether MS is a true pathophysiological condition or* Corresponding author. Tel.: +39 011 6335 006; fax: +39 011 6961 045.
E-mail address: mario.bo@unito.it (M. Bo).
0167-4943/$ – see front matter  2008 Published by Elsevier Ireland Ltd.
doi:10.1016/j.archger.2007.12.003merely a variegated cluster of risk factors produced by expert
groups (Kahn et al., 2005; Reaven, 2005; Grundy, 2006a). The
prevalence of MS is reported to rise dramatically with increasing
age (Ford et al., 2002; Cameron et al., 2004). However, aging per se
is associated with increased incidence and prevalence of most of
the abnormalities contributing to the MS, including reduced lean/
fat mass ratio, hypertension, alterations in glucose homeostasis
and decreased high density lipoprotein (HDL) concentration.While
it appears plausible that at young-adult age a single pathophy-
siological alteration (increased visceral adipose tissue and/or
insulin-resistance) might drive the early and unusual clustering of
metabolic abnormalities (dyslipidemia, hypertension, abnormal
glucose tolerance and inflammation) (Shen et al., 2003; Bo et al.,
2004; Kahn et al., 2005; Reaven, 2005; Pladevall et al., 2006), it
seems much more hazardous to cluster in a syndrome risk factors
which are extremely common in older subjects. Therefore,
whether MS in older people consistently identifies a true
pathophysiological entity or a casual aggregation of aging-
associated metabolic abnormalities remains to be fully elucidated.
Table 1
Characteristics of the sample at baseline
Parameters Values
Age (years) 73.1  4.7
SBP (mmHg) 142  17
DBP (mmHg) 87  8
Median BP (mmHg) 106  10
BMI (kg/m2) 25.4 3.5
Waist circumference (cm) 96  12.5
Fasting glucose (mg/dl) 90.9  13.3
Fasting insulin (mU/l)a 16.5 (13.2–19.8)
HOMA-IRa 3.73 (2.7–5.0)
TC (mg/dl)a 217.5 (187.0–240.2)
HDL-C (mg/dl) 64.3  15.2
LDL-C (mg/dl)a 128.2 (106.5–150.3)
TG (mg/dl)a 107.5 (83.5–134.2)
Apo-B (mg/dl)a 108 (95.2–132.8)
CRP (mg/l)a 1.85 (0.8–3.8)
Fibrinogen (mg/dl) 386  70
Erythrocyte sedimentation rate (mm/h) 16.7 11.6
Creatinine (mg/dl)a 0.81 (0.75–0.95)
Mean  S.D., unless otherwise indicated.
a Median and interquartile range.
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non-diabetic subjects the aggregation of metabolic components
contributing to the MS is consistent with a common single
syndromic variable. Therefore, several statistical procedures were
used to assess whether a model with a single latent variable may
account for the variables contributing to MS in older subjects.
2. Subjects and methods
An invitation to participate to the study was sent to five general
practitionersworking in different districts of themetropolitan area
in Turin. A detailed description of the study, including design, aims
and inclusion/exclusion criteria, was provided. A descriptive letter
of the studywas attached for eligible patients, in order to obtain an
informed consent to participation.Men aged 70 years or olderwere
eligible to the study. Further inclusion criteria were independence
in daily living, i.e., score<1 on the index of activities of daily living
(ADL) (Katz et al., 1963) and absence of cognitive impairment, i.e.,
score <4, on the short portable mental status questionnaire
(SPMSQ) (Pfeiffer, 1975). Exclusion criteria were: known diabetes,
hepatic or renal failure, conditions or disorders affecting metabo-
lism, use of lipid-lowering drugs in the previous month, neoplasm
or other severe diseases. Eligible subjects were enrolled in the
period September–October 2006.
A detailed medical history was collected and the following
variables were considered: age, smoking habits, alcohol consump-
tion, and cardiovascular history. In each patient the following
measures were obtained: weight (kg), height (m), bodymass index
(BMI), calculated according to the formulaweight (kg)/height (m2),
waist and hip circumferences (cm) measured according to current
guidelines (WHO, 1995), systolic and diastolic blood pressure (SBP
andDBP, respectively) (mean value of 3measures obtainedwith an
appropriately sized cuff and standard mercury sphygmoman-
ometer at the non-dominant upper arm after a 5-min rest in the
supine position).
Blood samples were collected from an antecubital vein into
vacutainer tubes containing EDTA after a 12-h overnight fast for
routine blood chemistry, measurement of plasma lipid and
lipoprotein levels, coagulative and inflammatory variables. Total
cholesterol (TC) and triglycerides (TG) were measured using
standard commercial enzymatic kits (CHOD-PAP and GPO-PAP
methods, Roche Diagnostics, Mannheim, Germany). HDL-cho-
lesterol (HDL-C) levels were measured through enzymatic
colorimetric assay by a direct method (ADVIA 1650/2400, Bayer,
Milano, Italy) after separation of cholesterol from non-HDL
particles. LDL-cholesterol (LDL-C) concentration was calculated
according to the formula of Friedewald et al. (1972). Plasma
fibrinogen was quantified automatically through a functional
coagulative assay according to the Clauss method (STA-Fibrino-
gen, Roche). Pentameric C-reactive protein (pCRP) levels were
measured with a highly sensitive immunoassay that used a
monoclonal antibody coated with polistirene particles; the assay
was performed using a Behring BN-100 nephelometer (DADE
Behring, Marburg, Germany), according to the method described
by the manufacturer (Ledue et al., 1998; Roberts et al., 2001).
Glucose was enzymatically determined by the hexokinase
method. Serum insulin was determined by monoclonal antibody
method (Insulin IRMA CT, RADIM, Pomezia, Italy). Insulin-
resistance was calculated through the homeostasis model
assessment (HOMA) according to the formula: fasting serum
insulin (mU/ml)  fasting plasma glucose (mmol/l)/22.5 (Galvin
et al., 1992; Bonora et al., 2000).
Diagnosis of MS was made according to the NCEP-ATP III
guidelines (Expert Panel, 2001). Participants taking anti-hyper-
tensive medications were counted as meeting the blood pressurecriterion (He et al., 2006). Patients with a new finding of diabetes
were not included in the study.
The study protocol agreed with the recommendations of the
World Medical Association for biomedical research involving
human subjects.
2.1. Statistical analysis
The sample size was defined according to the structural
equation modeling. In the absence of a definite rule, we adopted
one of the several arbitrary ‘‘rules of thumb’’ proposed: at least 10
cases for item according to Bryant and Yarnold (1995) and at least
100 cases overall according to Hatcher et al. (1995).
Data were analyzed using SPSS for Windows 12 and Tetrad 4.0.
Frequencies, mean and standard deviation (SD), skewness and
kurtosis were calculated. Non-normally distributed variables were
normalized according to Blom (1959). The Cronbach alpha test
(score range 0–1: a score of 1 defines the maximal internal
consistency) was used to assess the internal consistency of the
components contributing to MS. The structural equation modeling
methodology was used to assess the fit to a model with a single
latent variable. Thiswas assessed using theNFI, the RMSEA, the CFI,
and the TLI. These fit indexes were appropriately used to minimize
the effect of the sample size on the x2 values. The score range for
NFI, CFI and TLI is 0–1: a score of 1 identifies the optimal fit, and
score 0.9 are usually considered expression of a good fit. For the
TLI negative values are considered equal to 0. For the RMSEA,
negative values are conventionally considered equal to 0; values
<0.05 suggest a good fit.
3. Results
A total of 156 subjects were selected for the study. Three of
them received a new diagnosis of diabetes andwere excluded from
the study; one subject refused to participate. Analysis was
conducted on 152 subjects.
Characteristics of the sample investigated are shown in Table 1.
Mean age was 73.1  4.7 years. SBP values 130 mmHg and DBP
values85 mmHgwere found in 128 (84.2%) and 98 (64.5%) subjects,
respectively; 94 subjects (61.8%) had elevated SBP and DBP. Seventy
subjects (46%) were on anti-hypertensive medication. Mean waist
circumference was 96.0  12.5 cm and 92 subjects (60.5%) had
central obesity according to the NCEP-ATP III criteria. Mean fasting
Fig. 1. Structural equationmodeling, with blood pressure considered as a dichotomous variable (hypertension) on the left and considered as a continuous variable on the right
side of the scheme. *Triglyceridemia was normalized according to Blom (1959).
Table 2
Results of fit indices with BP considered as a dichotomous variable (A) and
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glucose >110 mg/dl. Median TG value was 107.5 mg/dl and 26
subjects (17.1%) had values exceeding 150 mg/dl. Mean HDL-C was
64.3  15.2 mg/dl; values lower than 40 mg/dl were observed in 6
subjects (3.9%).
The presence of MS according to the NCEP-ATP III criteria was
diagnosed in 40 subjects (26.3%). The most common clusters
accounting for diagnosis of MS were hypertension-impaired
fasting glucose-central obesity (41%), hypertension-central obe-
sity-hypertriglyceridemia (19%), hypertension-impaired fasting
glucose-hypertriglyceridemia (12%).
The Cronbach alpha test showed low internal consistency
among the metabolic variables (a = 0.31). Results of the structural
equation modeling are shown in Fig. 1 and Table 2. The calculated
x2 were 28.31 and 32.52 for the model entering hypertension as
dichotomous variable and for the model entering blood pressure
values, respectively, both expressing low fit to a model with a
single latent variable. In bothmodels, CFI (0.41 and 0.55), NFI (0.59
and 0.55), RMSEA (0.25 and 0.22) and TLI (0.31 and0.12) scores
showed a low fit of the metabolic alterations to a single latent
variable. As a whole, these results suggest that in this sample of
older subjects, a single latent variable may not account for
variables contributing to the definition of the MS.
4. Discussion
The results of the present study suggest that MS should not
always be regarded as a coherent clinical entity in older subjects. In
this sample of healthy older subjects, the structural equation
modeling showed that the metabolic components act as indepen-dent variables. Moreover, fit model analysis (NFI, RMSEA, CFI and
TLI) and Cronbach test demonstrated a poor internal consistency of
the MS. As a whole, these findings suggest caution in making
diagnosis of MS at older ages, since metabolic and cardiovascular
abnormalities, which are per se extremely common in elderly
people, do not appear to cluster together under a single common
factor.
Several approaches have been used to confirm the existence of
MS and to identify its pathophysiological mechanisms. At first,
epidemiologic surveys demonstrated that the aggregation of some
metabolic alterationswasmore frequent thanwould be expectedby
chance (Ramachandran et al., 1998; Wilson et al., 1999). Several
studies used different factorial analyses to explore the underlying
structure of the MS (Godsland et al., 1998; Gray et al., 1998; Levya
et al., 1998; Chen et al., 1999; Kekalainen et al., 1999; Lempiainen
et al., 1999). Lempiainen et al. (1999) showed that BMI,waist-to-hip
ratio, TG, fasting plasma glucose and insulin clustered on a single
factor in both sexes; in a similar study on younger non-diabetic
subjects (Meigs et al., 1997), 3 distinct factorswere found, the first of
them including hyperinsulinemia, hyperglycemia, high levels of TG,
low HDL-C, high BMI and high waist-to-hip ratio. A separate
hypertension factor was reported by both authors. However, a
common soil of the syndrome was not identified in most of these
studies, and factorial analyses steadily showed the presence of three
ormoremetabolic clusters within the syndrome. This is specifically
the case of blood pressure values, which have been shown to
aggregate separately from other metabolic clusters. Pladevall et al.
(2006) used confirmatory factor analysis on three large patient
datasets. They showed that insulin-resistance, mean arterial
pressure, TG-to-HDL-ratio and waist circumference clustered
together under a single latent factor, suggesting the existence of a
common causal factor underlying these different components.
However, they used an original approach introducing only one
measure for each of the four postulated metabolic syndrome
components, namely HOMA-IR for insulin-resistance, mean arterial
pressure for SBP and DBP values, the ratio of TG-to-HDL-C for the
dyslipidemia trait, and waist circumference for central obesity. In
our view, such a pathophysiological approach profoundly differs
from theNCEP-ATP III diagnostic criteria currently recommended to
recognize the MS in the clinical practice.
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cardiovascular risk factor and the coexistence of such alterations in
a single person can be the result of two mechanisms: coincidence
or clustering. It is no matter of discussion that aging is associated
through several pathophysiological mechanisms with an increas-
ing prevalence of risk factors and that, as a consequence, this
frequent coexistence of multiple metabolic alterations makes it
easier to reach the number of criteria necessary for the diagnosis of
MS. However, coexistence does not imply clustering, the latter
being supported either by statistical and biological links. As an
example of this assumption, we can consider how the prevalence
of MS in this sample of older subjects changed when substituting
the International Diabetes Federation (IDF) criteria (Alberti et al.,
2005) for the NCEP-ATP III criteria: 16.1% vs. 26.3%. These two
definitions are considered very congruent (Grundy, 2006b)
because each contains five virtually identical components;
however, they substantially differ in that the IDF definition
requires themandatory presence of central obesity. Central obesity
was agreed as essential, because of the evidence linking waist
circumference with cardiovascular disease and the other MS
components, and the likelihood that central obesity is an early step
in the etiological cascade leading to full MS. Therefore, although
the criteria are identical, those endorsed by the IDF underscore the
potential pathophysiological mechanisms more strongly than the
simple aggregation of components in the NCEP-ATP III definition
does.
Beyond the skepticism on the common biological basis for the
diagnostic NCEP-ATP III algorithm, our findings in older subjects
provide some evidence that there is low internal consistency
among themetabolic variables and that a single latent factormight
not account for variables contributing to the definition of the MS.
There have been very few scientific evidence presented or
discussed for why the ATP III algorithm is what it is and several
concerns have been raised about the arbitrary cut-off selected for
most of the metabolic components (Kahn, 2006). Moreover, these
items have not been critically addressed in older subjects, who
usually have the greatest burden of cardiovascular and metabolic
risk factors. On this background, we decided to use a comprehen-
sive approach to evaluate either the internal consistency of the
syndrome (with the Cronbach alpha test) and the fit of the
components to a single latent variable (through the structural
equation modeling as confirmatory factor analysis) specifically in
older subjects (Kline, 1998; Shen et al., 2003; Lawlor et al., 2004b).
Structural equationmodeling implies an ‘‘a priori’’ definition of the
number of factors to be extracted; we decided to extract a single
latent factor, i.e., the MS that we hypothesized to be a
pathophysiological entity.
Most important, the present study was not addressed to
investigate the consistency of the biological mechanisms under-
lying the MS, but just to evaluate the statistical coherence of it
among older healthy subjects. Therefore, biological inferences
should not be made on the basis of these findings.
Some limitations of the present study must be addressed.
Despite the limited sample size, the prevalence of MS observed in
our study was keeping with results of previous studies (Lawlor
et al., 2004a; He et al., 2006; McNeill et al., 2006; Ravaglia et al.,
2006; Sundstrom et al., 2006b) and slightly higher than that
reported in recent national surveys (Wannamethee et al., 2005b,
2006; Cankurtaran et al., 2006; Maggio et al., 2006). Only older
men were enrolled in this study, which obviously limits the
generalization of these findings. There was a high prevalence of
subjectswith blood pressure values above theNCEP-ATP III systolic
and diastolic cut-off values. However, most of these subjects were
currently receiving blood pressure lowering drugs. Patients were
considered hypertensive either when treated with anti-hyperten-sive drugs or when they had blood pressure values exceeding the
cut-off valueswithout anti-hypertensive treatment. Analysis of the
blood pressure variable was performed either introducing
dichotomous and continuous variables. Further concerns about
the possibility to extend our observations to a general population
of aged subjects could be raised because of the very low prevalence
of hypo-HDL-C. This can be largely explained by our decision to
enroll healthy independent elderly, who, on the other hand, would
be the main target of geriatric cardiovascular prevention.
There remain several uncertainties about the utility in
diagnosing MS in older subjects. Several studies (Yarnell et al.,
1998; Lawlor et al., 2004b; Wilson et al., 2005; Sundstrom et al.,
2006a,b) showed that the risk of cardiovascular diseases associated
with the syndrome is not greater than that explained by the
presence of its single components. Other studies demonstrated
thatMS does not consistently predict adverse events andmortality
in elderly patients (McNeill et al., 2006; Ravaglia et al., 2006;
Sundstrom et al., 2006b). However, the basic question is whether
we know enough about this constellation of risk factors to warrant
adopting a unique clinical construct that has value to either
physicians or patients. On this point, our findings demonstrate that
in a sample of healthy older subjects there is low internal
consistency among the metabolic variables and that there is a low
fit of these variables to a single latentmodel. These findings should
suggest caution in labeling as MS any aggregation of metabolic
abnormalities according to the NCEP-ATP III ‘‘three out of five’’ rule
(Dominiczak, 2006); some of these patients will have MS, some of
them will suffer from multiple risk factors. In light of persisting
uncertainties about predictive value of MS above that of its single
components in this age group, physician should be addressed to
recognize and treat metabolic abnormalities either they are part of
MS or not.
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